

OCTOBER 16-19, 2024
CHICAGO, ILLINOIS



Chicago Specials

Fall Group Meeting

Lung Committee

Lung Committee

Leadership

Chair: Jhanelle E. Gray, MD
 Vice-Chair: Roy S. Herbst, MD, PhD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Mary Redman, PhD
 Yingqi Zhao, PhD
 Kari Chansky, MS
 Mia Hsieh, MS
 Katie Minichiello, MS
 Jieling Miao, MS
 James Moon, MS

Scientific Leadership

Translational Medicine:
 Biology/Pathology: Philip C. Mack, PhD
 Fred R. Hirsch, MD, PhD
 Ignacio I. Wistuba MD
 Imaging: Chadwick L. Wright MD, PhD
 Myrna C. Godoy, MD, PhD
 Radiation Oncology: Henry Park, MD
 Surgery: Wayne L. Hofstetter, MD
 Subcommittee Chairs:
 Early Stage Disease: Wayne L. Hofstetter, MD
 Raymond Osarogiagbon, MD
 Locally Advanced Disease: Shirish Gadgeel, MD (Early Therapeutics)
 Metastatic Disease: Ross Camidge, MD
 Karen Reckamp, MD
 Community Engagement: Paul J. Hesketh, MD
 Suzanne Cole, MD

Designates

Cancer Control Liaison: Gary E. Goodman, MD
 DEI Champion: Lucy Gansauer, MSN, RN, OCN, CCRP
 Veterans Affairs: Chao H. Huang, MD
 Data Coordinators: Amy Johnson, CCRP
 Kevin Moralda, BS
 Larry Kaye
 Louise Highleyman, BA
 Pasarlai Ahmadzai, MD, MPH
 Clinical Research Project Manager: TBD
 Oncology Research Professionals:
 CRA: TBD
 Nurses: Rosalie Zablocki, RN
 Lisa G. Davis, RN
 Patient Advocate: Judy Johnson, MBA

Pharmaceutical Science: Joyce Lee, PharmD
 Safae Ghouraiichi, PharmD
 Protocol Project Managers: Justine Trevino
 Gabe Chadwell (Lung-MAP)
 Sr. Protocol Project Manager: Jennifer Beeler (Lung-MAP)
 Clinical Trials Program Manager: Mariah Norman, MS
 Crystal Miwa (Lung-MAP)

Time/Location

Friday, October 18, 2024 3:00 p.m. - 6:00 p.m.
 Room: Regency A (Ballroom Level, West Tower)

Agenda

3:00 - 3:15 pm **General Update & Accruals:** Jhanelle E. Gray, MD

3:15 - 3:20 pm **Patient Advocate Update:** Judy Johnson, MBA

3:20 - 3:25 pm **Thoracic Surgery Session:** Eric Toloza, MD, PhD

3:25 - 3:30 pm **Thoracic Radiation Session:** Megan Daly, MD

3:30 - 3:35 pm **Translational Medicine Session:** Philip C. Mack, PhD

3:35 - 3:40 pm **Community Engagement Core:** Paul J. Hesketh, MD

3:40 - 3:45 pm **DEI Session:** Lucy Gansauer, MSN, RN

3:45 - 4:20 pm **Role of Pathologic Response Assessment in Resectable NSCLC** - Sanja Dacic, MD, PhD, Professor of Pathology, Vice Chair & Director of Anatomic Pathology, Pathology Medical Director, Tumor Profiling Laboratory, Yale School of Medicine

4:20 - 4:55 pm **Thoracic Medical Oncology:** Jhanelle Gray, MD

S2302, "Project Pragmatica-Lung Trial." Dr. Karen Reckamp. Activated: 3/6/23; Accrual Goal: 700; Accrual: 608

LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung- Map Screening Study)." Drs. Karen Reckamp and David Gandara (SWOG). Activated: 1/28/19; Accrual Goal: 6000; Accrual: 3467.

S1900E, "A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB- STUDY)." Dr. Karen Reckamp (SWOG). Dr. Suki Padda and Dr. David Gerber (ECOG). Activated: 4/2/21; Accrual Goal: 116; Accrual: 241.

Lung Committee

S1900G, "A Randomized Phase II Study of Capmatinib plus Osimertinib (Tagrisso) with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)". Dr. Sarah Goldberg and Dr. Ross Camidge (SWOG). Activated: 4/3/23; Accrual Goal: 66 (60 eligible); Accrual: 21.

S1900K, "A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Dr. Paul Paik and Dr. Xiuning Le. Activated: 12/18/23; Accrual Goal: 56; Accrual: 5.

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Dr. Chad Rusthoven (SWOG). Activated: 1/10/20; Accrual Goal: 668; Accrual: 233.

S1933, "A Pilot Trial of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Dr. Raid Aljumaily (SWOG). Activated: 6/15/20; Accrual Goal: 47; Accrual: 39.

S1914, "A Randomized Phase III trial of Induction/Consolidation Atezolizumab +SBRT versus SBRT Alone in High risk, Early Stage NSCLC." Dr. Megan Daly (SWOG). Activated: 3/25/20; Accrual Goal: 480; Accrual: 412.

4:55 - 6:00 pm **Open Discussion**

Active Studies

LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)." Drs. Borghaei, Reckamp, Gandara, et al. Activation: 1/28/19.

S1900E, "A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)." Drs. Padda and Gerber. Activation: 4/2/21.

S1900G, "A Randomized Phase II Study of INC280 (Capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Goldberg and Camidge. Activation: 4/3/23.

S1900K, "A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Paik and Le. Activation: 12/18/23.

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Drs. Rusthoven, Brown, Wefel, et al. Activation: 1/10/20.

S1914, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activation: 3/25/20.

S1933, "A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Drs. Aljumaily, Mitin, and Wozniak. Activation: 6/15/20.

S2302, "PRAGMATICA: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer" Drs. Reckamp and Dragnev. Activation: 3/6/23.

CTSU/A081801, "Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)." Dr. Gray. Activation: 6/3/20.

CTSU/A151216, "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)." Dr. Gandara. Activation: 8/18/14.

CTSU/EA5182, "Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)." Dr. Goldberg. Activated: 10/22/20.

CTSU/NRG-LU007, "Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial." Dr. Park. Activated: 8/17/20.

Closed Studies

CTSU/NRG-CC003, "Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer." Dr. Gaspar. Activation: 12/7/15; Temporary closure: 5/28/20; Reactivation: 7/27/20; Permanent closure: 6/21/22.

Lung Committee

S1800A, "A Phase II Randomized Study of Ramucirumab Plus Pembrolizumab (MK-3475) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Reckamp and Dragnev. Activation: 5/17/19. Permanently closed: 10/20/20.

S1800D, "A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)." Drs. Wrangle and Husain. Activation: 2/15/22. Permanently closed: 3/10/23.

S1900A, "A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Riess and Wheatley-Price. Activation: 1/28/19. Permanently closed: 2/2/21.

S1900B, "A Phase II Study of Selpercatinib (LOXO-292) in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Elamin and Gray. Activation: 2/10/20. Permanently closed: 5/1/21.

S1900C, "A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)." Drs. Skoulidis and Suga. Activation: 1/16/20. Permanently closed: 12/18/20.

S1900F, "A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY352723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)." Drs. Gray and Elamin. Activation: 7/25/22. Permanently closed: 6/27/23.

S1929, "Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Drs. Karim, Reckamp, Gay, et al. Activation: 6/15/20; Step 1 Registration Permanently Closed 8/15/22; Step 2 Permanently Closed 10/15/22.

S1934, "NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer." Drs. Osarogiagbon, Huang, Decker, et al. Activation: 9/9/21; Temporary closure: 11/5/21; Reactivation: 2/15/22; Permanently closed 3/1/23.

CTSU/EA5163/S1709, "INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis." Dr. Chiang. Activation: 2/28/19. ; Closed to accrual: 3/1/24.

S1701, "A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma." Drs. Tsao and Koczywas. Activation: 8/9/18; Closed to accrual: 10/15/22.

CTSU/E4512, "A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein." Dr. Li. Activation: 8/18/14; Closed to accrual: 5/10/24.

CTSU/EA5181, "Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC." Dr. Harkenrider. Activation: 4/9/20; Closed to accrual: 11/20/23.

CTSU/NRG-LU002, "Maintenance Systemic Therapy versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial." Dr. Gomez. Activation: 4/7/17; Temporary closure: 11/12/21; Closed to accrual: 12/06/23.

CTSU/NRG-LU005, "Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab." Dr. Hsu. Activation: 5/28/19; Closed to US and Canadian sites 6/23/22; Closed to accrual: 12/31/23.

CTSU/EA5191, "A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC." Dr. Massarelli. Activated: 5/22/20; Closed to accrual: 10/13/23.

NCI-Approved Concepts

S1900J, "A Phase II Study of Amivantamab SC (subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Rolfo and Gadgeel.

S1800E, "A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Waqar and Li.

Lung Committee

S2404, “Accelerating Drug Efficacy Evaluation thru Growth Rate and Overall Survival Correlations” Dr. Lawrence Schwartz and Dr. Karen Reckamp.

Concepts in Development

S1900N, “A Phase II Study of Sacituzumab Govitecan and Ivonescimab in Participants with Relapsed/Refractory Advanced Non-Small-Cell Lung Cancer with Actionable Genomic Alteration (Lung-MAP Sub-Study).” Drs. Scott and Riess.

S2409, “PRISM: PReclision in SCLC via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)” Drs. Chiang, Chiappori, Kim, et al.

S2414, “Incorporating Pathologic Response in Patients with Early Stage Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting (INSIGHT).” Drs. Cetnar and Osarogiabon.

Publications

The publications listed below were received by the Group Chair’s Office as published (including online), accepted, or submitted since the SWOG Spring 2024 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

S1929 Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929. Abdel Karim N, Miao J, Reckamp K, Gay C, Byers L, Zhao Y, Redman M, Carrizosa D, Wang W, Petty W, Mehta K, Faller B, Agamah E, Kasbari S, Malisetti R, Kumar A, Schallenkamp J, Alluri K, Gray J, Kelly K. Accepted 2024.

S1400 Lung-MAP Next Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400). Kozono D, Hua X, Wu M, Tolba K, Waqar S, Dragnev K, Cheng H, Hirsch FR, Mack P, Gray JE, Kelly K, Borghaei H, Herbst RS, Gandara DR, Redman M. Accepted 2024.

S2302 Pragmaticism in Cancer Clinical Trials. Sankar K, Redman M, Dragnev K, Henick B, Iams W, Blanke C, Herbst R, Gray J, Reckamp K. *ASCO Educational Book*, Jun;44(3):e100040, 2024. <https://pubmed.ncbi.nlm.nih.gov/38771997/>

LUNGMAP A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol. Neal JW,

Minichiello K, Brennick R, Huang RSP, Hiemenz MC, Amler C, Patel J, Herbst R, Reckamp KL, Borghaei H, Highleyman L, Redman MW, Pasquina LW, Kozono DE. *Oncologist* Jun 3;29(6):e843-e847, 2024. <https://pubmed.ncbi.nlm.nih.gov/38597608/>

EAY131 Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A. Gettinger SN, Song Z, Reckamp KL, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Kong XT, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O’Dwyer PJ, Chen AP, Flaherty KT. *JCO Precision Oncology* Jul;8:e2300725, 2024. <https://pubmed.ncbi.nlm.nih.gov/38986051/>

Submitted Manuscripts

S0819 External validation of a novel computed tomography-based prognostic radiomic signature in patients with metastatic non-small cell lung cancer:correlative analysis of SWOG S0819 phase III randomized trial. Dercle L, Gomez D, Zhao B, Hama J, Kelly K, Redman M, Gandara D, Schwartz L, Gray JE. Submitted 2024.

S1701 S1701, A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma. Tsao A, Hsieh M, Koczywas M, Tu J, Riess J, Tanvetyanon T, Ma B, Zhao Y, Redman M, Edelman M, Gandara D, Gray J, Kelly K. Submitted 2024.

Lung Committee

Accrual from trials that are open as of 6/30/2024 or have closed in the prior 18 Months by Institution and Study

	LUNGMAP	S1800D	S1827	S1900E	S1900G	S1914	S1933	S2302	A081801	A082002	A151216
Ascension Providence Hospitals - Southfield	13	-	-	-	-	-	-	-	-	-	15
Ascension Via Christi Hospitals Wichita	1	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	1	-	-	-	-	-	1	-	1
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	2	-	-	7
Baptist Mem Health Care/Mid South MU-NCORP	36	-	2	2	-	8	1	10	4	-	26
Baylor College of Medicine/Duncan CCC	-	-	3	-	-	-	-	-	-	-	-
Boston Medical Center	-	-	5	-	-	-	-	2	-	-	3
CWRU Case Comprehensive CC LAPS	11	-	2	2	-	-	-	14	11	-	55
Ca Res Consort of W Mich NCORPP	3	-	-	-	-	5	-	1	-	-	1
Cancer Research for the Ozarks NCORP	39	3	-	-	-	7	4	4	-	-	1
Ca Res of Wisconsin and N Mich Consort	28	2	3	4	-	6	-	2	-	-	-
Carle Cancer Center NCORP	3	-	1	1	-	6	-	8	-	-	-
Cedars-Sinai Medical Center	21	-	-	1	1	4	-	8	-	-	-
City of Hope Comprehensive Cancer Center	5	-	1	-	-	-	-	2	-	-	5
Columbia U MU NCORP	13	-	-	-	-	-	1	5	-	-	-
Columbus NCORP	28	-	5	-	-	-	-	3	-	-	-
CommonSpirit Health Research Institute	39	-	1	-	-	1	-	1	-	-	2
Corewell Health William Beaumont U Hospital	-	-	-	-	-	-	-	-	-	-	2
Cotton O'Neil CC / Stormont Vail Hlth	-	-	-	-	-	-	-	-	-	-	3
Dayton NCORP	2	-	-	-	-	-	-	-	1	-	8
Duke University - Duke Cancer Institute LAPS	-	-	-	-	-	-	-	1	-	-	-
Essentia Hlth NCORP	16	2	-	-	-	3	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	4	-	-	-	-	-	-	3	-	-	15
Froedtert & the Med College of Wisconsin LAPSS	2	-	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	6	-	1	-	-	2	1	-	-	-	-
Georgia NCORP	63	4	3	1	-	9	-	11	-	-	9
Gulf South Minority Underserved NCORP	24	1	1	-	-	3	-	5	1	-	1
Hawaii Minority Underserved NCORP	27	-	2	-	-	-	-	5	-	-	-
Heartland Cancer Research NCORP	149	9	9	5	-	36	4	41	-	-	-
Henry Ford Hospital	7	-	-	-	-	-	-	-	2	-	29
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-	-	8
Instituto Nacional De Cancerologia de Mexico	-	-	5	-	-	-	-	-	-	-	-
Kaiser Permanente NCORP	88	6	-	8	-	3	-	19	5	-	206
Kansas City Veterans Affairs Medical Center	-	-	-	-	-	-	-	1	-	-	-
Lahey Hospital and Medical Center	32	-	-	-	-	4	2	10	-	-	30
Loma Linda University Medical Center	6	-	-	-	-	-	-	-	-	-	10
Loyola University Medical Center	25	1	-	-	-	1	-	4	-	-	25
MAVERIC	73	3	3	1	-	-	-	7	11	-	32
Med U South Carolina MU NCORP	19	1	-	2	1	-	-	10	-	-	-
Mercy Medical Center - Des Moines	8	-	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	108	4	2	7	1	11	-	11	-	-	-
Mission Hospital	1	-	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	17	1	1	1	1	-	-	32	20	-	83
Montana Cancer Consortium NCORP	25	-	-	1	-	1	1	1	-	-	-
Mount Sinai Hospital	-	-	-	-	-	9	-	2	-	-	-

Lung Committee

Accrual from trials that are open as of 6/30/2024 or have closed in the prior 18 Months by Institution and Study

	LUNGMAP	S1800D	S1827	S1900E	S1900G	S1914	S1933	S2302	A081801	A082002	A151216
MultiCare Tacoma General Hospital	-	-	-	-	-	-	-	2	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	20	-	-	1	-	-	-	-	-	-	1
National Cancer Center-Korea	-	-	1	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	14	-	-	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	97	-	1	2	-	8	1	2	-	-	-
Northwell Health NCORP	-	-	-	-	-	1	-	-	1	-	3
Northwestern University LAPS	26	2	1	-	-	-	-	14	-	-	-
Oregon Health and Science University	10	1	-	-	-	1	-	-	8	-	24
Pacific Cancer Research Consortium NCORP	20	-	-	-	-	-	-	-	-	-	4
SCL Health Saint Joseph Hospital	1	-	-	-	-	1	-	-	1	-	3
Salem Hospital	7	-	-	2	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	51	1	7	1	-	13	-	6	-	-	-
Sutter Cancer Research Consortium	29	-	-	1	-	-	-	-	-	1	11
The Don and Sybil Harrington Cancer Center	13	2	-	-	-	-	-	-	-	-	-
James Graham Brown CC at U Louisville	-	-	-	-	-	-	-	-	-	-	5
UC Davis Comprehensive Cancer Center LAPS	40	6	1	1	1	11	-	11	-	2	46
UC Irvine Hlth/Chao Family CCCr	29	-	1	-	-	5	-	1	-	-	15
UC San Diego Moores Cancer Center	15	-	-	1	-	-	-	-	-	-	5
UPMC Hillman Cancer Center LAPS	74	5	9	7	-	2	4	10	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	5	-	-	6	-	3	-	-	12
U of Alabama at Birm/Deep South Res Cnsrt LAPS	-	-	-	-	-	-	-	11	-	-	-
University of Arkansas for Medical Sciences	11	1	-	-	-	16	-	8	-	-	3
U of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	-	-	-	24
University of Colorado Cancer Center LAPS	14	-	4	-	1	5	-	3	2	-	58
U of Kansas C C - MCA Rural MU NCORP	96	1	1	1	-	-	-	3	1	-	31
University of Kentucky/Markey Cancer Center	51	-	1	-	-	-	-	7	-	1	5
U of Michigan Comprehensive CC LAPS	1	-	-	-	-	-	-	2	-	-	62
University of Mississippi Medical Center	1	-	-	-	-	-	-	-	-	-	26
U of Oklahoma Health Sciences Center LAPS	33	-	1	-	-	3	13	7	-	-	-
University of Rochester LAPS	67	2	-	6	-	3	-	10	-	-	-
U of Texas Health Science Center at San Antonio	-	-	-	-	-	-	-	16	-	-	-
U of Texas MD Anderson Cancer Center LAPS	3	-	5	-	-	5	-	-	-	-	2
U of Utah - Huntsman Cancer Institute LAPS	-	-	4	-	-	5	-	4	-	-	-
Upstate Carolina NCORP	39	-	3	-	-	2	-	-	-	-	-
Vanderbilt U - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	3	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	1	-	-	-	-	-	-	-	-	-	1
Western States Cancer Research NCORP	2	-	-	-	-	-	-	-	-	-	1
Wisconsin NCORP	40	-	1	1	-	13	-	3	-	-	-
Yale University - Yale Cancer Center LAPS	25	-	4	3	1	10	-	11	7	-	57
ALLIANCE	822	15	21	21	3	38	5	90	-	-	-
CCTG	-	-	31	-	-	-	-	-	-	-	-
ECOG-ACRIN	353	5	8	19	-	27	-	46	-	-	-
NRG	456	4	66	12	2	88	1	29	-	-	-
Total	3,403	82	227	115	12	382	38	527	76	4	976

Lung Committee

Accrual from trials that are open as of 6/30/2024 or have closed in the prior 18 Months by Institution and Study

	E4512	EA5162	EA5163	EA5181	EA5182	EA5191	NRGLU002	NRGLU005	NRGLU006	NRGLU008	R1308
Ascension Providence Hospitals - Southfield	2	1	2	3	-	1	-	-	-	-	-
Ascension Via Christi Hospitals Wichita	-	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	-	-	-	2	-	-	-
Banner University Medical Center - Tucson	2	-	-	10	-	-	-	1	-	-	-
Baptist Mem Health Care/Mid South MU-NCORP	-	-	1	1	2	-	1	4	-	-	-
Baylor College of Medicine/Duncan CCC	-	-	-	-	-	-	-	-	3	-	-
Boston Medical Center	-	-	-	2	-	-	-	-	-	-	-
CWRU Case Comprehensive CC LAPS	-	-	17	21	1	4	-	-	-	-	-
Ca Res Consort of W Mich NCORPP	-	-	-	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-	-	-	-
Ca Res of Wisconsin and N Mich Consort	-	-	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCORP	-	-	-	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-	-	-
Columbia U MU NCORP	-	-	-	1	-	-	-	-	-	-	-
Columbus NCORP	-	-	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-	-	-	-
Corewell Health William Beaumont U Hospital	-	-	-	-	-	-	-	-	-	-	-
Cotton O'Neil CC / Stormont Vail Hlth	-	-	-	-	-	-	-	-	-	-	-
Dayton NCORP	-	-	-	-	-	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-	-	-	-	-	-	-	-
Essentia Hlth NCORP	-	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	4	-	-	-	-	-	-	-
Froedtert & the Med College of Wisconsin LAPSS	-	-	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
Georgia NCORP	-	-	1	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	3	-	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	1	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	1	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCORP	6	-	8	-	6	-	-	-	-	-	-
Kansas City Veterans Affairs Medical Center	-	-	-	-	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	2	-	-	-	-	-	-	-	-
Loma Linda University Medical Center	-	-	-	-	-	-	-	-	-	-	1
Loyola University Medical Center	-	-	2	2	-	-	-	-	-	-	-
MAVERIC	-	-	3	-	-	2	-	-	-	-	-
Med U South Carolina MU NCORP	-	-	-	-	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
Mission Hospital	-	-	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	1	-	5	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	1	5	-	-	1	-	-	-

Lung Committee

Accrual from trials that are open as of 6/30/2024 or have closed in the prior 18 Months by Institution and Study

	E4512	E45162	E45163	E45181	E45182	E45191	NRGLU002	NRGLU005	NRGLU006	NRGLU008	R1308
MultiCare Tacoma General Hospital	-	-	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-	-	-	-	-
National Cancer Center-Korea	-	-	-	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	-	-	-	-	-
Northwestern University LAPS	-	-	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	-	-	-	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
SCL Health Saint Joseph Hospital	-	-	-	-	-	-	-	-	-	-	-
Salem Hospital	-	-	-	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	-	-	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	3	-	-	-	-	-	1	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	-	-	-	-
James Graham Brown CC at U Louisville	-	-	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	1	-	6	-	1	-	-	-	-	-	-
UC Irvine Hlth/Chao Family CCCr	1	-	-	-	-	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
U of Alabama at Birm/Deep South Res Cnsrt LAPS	-	-	-	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	1	-	1	3	-	-	-	1	-	-	-
U of Cincinnati Cancer Center-UC Medical Center	1	-	2	-	1	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	2	-	-	-	-	1	-	1	-	-	-
U of Kansas C C - MCA Rural MU NCORP	-	-	7	-	-	3	-	2	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-	-	-	-
U of Michigan Comprehensive C C LAPS	-	-	-	-	-	-	-	-	-	-	-
University of Mississippi Medical Center	-	-	-	-	-	-	-	-	-	-	-
U of Oklahoma Health Sciences Center LAPS	-	-	-	1	-	-	-	-	-	-	-
University of Rochester LAPS	-	-	6	19	-	-	-	1	-	-	-
U of Texas Health Science Center at San Antonio	-	-	2	-	-	-	-	-	-	-	-
U of Texas MD Anderson Cancer Center LAPS	1	-	-	-	-	-	-	-	-	-	-
U of Utah - Huntsman Cancer Institute LAPS	-	-	1	-	-	-	-	-	-	-	-
Upstate Carolina NCORP	-	-	-	-	-	-	-	-	-	-	-
Vanderbilt U - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	-	-	-	-	-	-	1	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	1	-	-	-	-	-	-
Wisconsin NCORP	-	-	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	4	-	14	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-	-
Total	22	1	84	72	17	11	2	13	3	1	1

